Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human... Key PointsQuestionDoes first-line everolimus plus endocrine therapy provide a clinical benefit for patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer? FindingsIn this phase 2, single-arm study, 202 patients treated with everolimus plus letrozole in the first-line setting achieved a median progression-free survival of 22.0 months; median overall survival was not reached. For 50 patients whose cancer progressed and who received continued treatment with everolimus plus exemestane, median progression-free survival was 3.7 months. MeaningThese results suggest a rationale for providing first-line everolimus plus letrozole therapy to patients with estrogen receptor–positive advanced breast cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Loading next page...
 
/lp/american-medical-association/everolimus-plus-endocrine-therapy-for-postmenopausal-women-with-v0sAJ1xXdO

References (24)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2018.0060
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionDoes first-line everolimus plus endocrine therapy provide a clinical benefit for patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer? FindingsIn this phase 2, single-arm study, 202 patients treated with everolimus plus letrozole in the first-line setting achieved a median progression-free survival of 22.0 months; median overall survival was not reached. For 50 patients whose cancer progressed and who received continued treatment with everolimus plus exemestane, median progression-free survival was 3.7 months. MeaningThese results suggest a rationale for providing first-line everolimus plus letrozole therapy to patients with estrogen receptor–positive advanced breast cancer.

Journal

JAMA OncologyAmerican Medical Association

Published: Jul 22, 2018

There are no references for this article.